RNS Number:4775R
Inion Oy
03 April 2008

                                    Inion Oy

                           ("Inion or the "Company")



                          Interim Management Statement



Tampere, Finland and Guildford, UK. 3 April 2008, Inion (LSE: IIN.L), a company
focused on the development and commercialisation of novel biodegradable medical
implants, is today issuing its Interim Management Statement ("IMS") for the
three months ended 31 March 2008.



Chris Lee, CEO of Inion, said: "We believe that Inion is turning the corner
following the reorganisation we undertook in 2007. As a result of this effort,
we are already seeing an increasing demand for our products compared with this
period last year. In the USA, we have built a substantial part of our
distributor network and are now focusing on getting the distributor sales force
fully trained and operational in order to accelerate sales towards our target in
2008 of at least 35% revenue growth on 2007."



Highlights



*          Invoiced sales for Q1 2008 are Euro824,000, with the order book at
Euro537,000 at the end of Q1 2008 (compared with Euro990,000 and Euro231,000,
respectively at the end of Q1 2007)



*          Clean room manufacturing staff numbers increased by 100% to 14 to
meet future anticipated increase in demand in 2008



*          The number of distributors appointed in the US has now increased to
40, with 34 focusing on the sales and distribution of speciality orthopaedics
products and six focusing on spine products sales



*          US commercial activity to focus on increasing active training and
management of current distributors to accelerate sales growth



*          Cash, cash equivalents and short-term investments totalled Euro13.8
million at 31 December 2007



                                     -ends-



For further information, please contact:


Inion Oy                                                Tel: +44 (0)1483 685390
Chris Lee, Chief Executive Officer
Julien Cotta, Chief Financial Officer


Citigate Dewe Rogerson                                  Tel: +44 (0)207 638 9571
Mark Swallow / David Dible




About Inion (www.inion.com)

Inion Oy is a medical devices company focused on the development and successful
commercialisation of innovative and unique biodegradable and bioactive surgical
implants in selected high value orthopaedic market segments.



Inion's core expertise and technology lies in the design and manufacture of
innovative biodegradable plates, screws, pins and membranes, which are used to
enhance the healing of bone or soft tissue injuries to the skeleton, such as
those caused by trauma or by reconstructive surgery. Inion implants are made
from its proprietary Inion Optima(TM) family of biomaterials, with properties
tailored for specific surgical applications, in terms of strength, flexibility
and rate of degradation


Inion is also focused on developing proprietary new bioactive and biodegradable
biomaterials that promote bone healing and accelerate patient rehabilitation.



Inion was incorporated in early 2000 and listed on the Official List of the UK
Listing Authority in December 2004 (ticker: IIN). The Company has offices in the
UK and USA, and its head office, R&D and production facilities are in Tampere,
Finland.



This announcement includes "forward-looking statements" which include all
statements other than statements of historical facts, including, without
limitation, those regarding the Group's financial position, business strategy,
plans and objectives of management for future operations (including development
plans and objectives relating to the Group's products), and any statements
preceded by, followed by or that include forward-looking terminology such as the
words "targets", "believes", "estimates", "expects", "aims", "intends", "will",
"can", "may", "anticipates", "would", "should", "could" or similar expressions
or the negative thereof. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors beyond the Group's
control that could cause the actual results, performance or achievements of the
Group to be materially different from future results, performance or
achievements expressed or implied by such forward-looking statements. Such
forward-looking statements are based on numerous assumptions regarding the
Group's present and future business strategies and the environment in which the
Group will operate in the future. Among the important factors that could cause
the Group's actual results, performance or achievements to differ materially
from those in forward-looking statements include those relating to Inion's
funding requirements, regulatory approvals, reliance on third parties,
intellectual property, key personnel and other factors. These forward-looking
statements speak only as at the date of this announcement. The Group expressly
disclaims any obligation or undertaking to disseminate any updates or revisions
to any forward-looking statements contained in this announcement to reflect any
change in the Group's expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based. As a result
of these factors, prospective investors are cautioned not to rely on any
forward-looking statement.






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

IMSBLGDSCUGGGID
Inion Oy (LSE:IIN)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Inion Oy Charts.
Inion Oy (LSE:IIN)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Inion Oy Charts.